“Inflammation in Atherosclerosis – A Translational Journey” (Virtual Event)

Peter Libby, MD
Cardiovascular Specialist and Mallinckrodt Professor of Medicine
Brigham and Women’s Hospital and Harvard Medical School

Peter Libby, MD, a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He directed Cardiovascular Medicine at BWH from 1998 – 2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to clinical translation. He instigated and helped to lead the large scale Canakinumab Anti-Inflammatory Thrombosis Outcomes Trial that provided clinical validation of the role of inflammation in atherosclerosis.

Dr. Libby has received numerous research awards, including the Distinguished Scientist Award from the American College of Cardiology (ACC), the Gold Medal of the European Society of Cardiology, the Basic Research Prize of the American Heart Association, the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society, the Ernst Jung Gold Medal for Medicine, and the Benditt Award from the North American Vascular Biology Organization. He is the recipient of the ACC Valentin Fuster Award for Innovation in Science for 2024.

Dr. Libby’s professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and honorary memberships in the British Atherosclerosis Society, the Japan Circulation Society, and the Japanese College of Cardiology. He has served as the President of the Association of University Cardiologists. He also has served as a volunteer for the American Heart Association, including chairman of several research committees and member of executive committees. He presided the ACC’s Research Peer Review Committee for two terms. He has frequently consulted for the National Heart, Lung, and Blood Institute, including membership on the Board of Scientific Councilors. He directed the DW Reynolds Cardiovascular Clinical Research Center and two cycles of Leducq Foundation Awards, and has received continuous funding from the US National Heart Lung and Blood Institute (NHLBI) for several decades.  He currently serves as the president of the International Atherosclerosis Society.

An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an Editor of Braunwald’s Heart Disease, and was the Editor-in Chief of the current 12th Edition. Dr. Libby has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. He has held numerous visiting professorships and delivered more than 150 major named or keynote lectures throughout the world.

Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and three honorary doctorates.

____________________________________________________________________________________________

Join Meeting!

OBJECTIVES:

• Analyze new information about traditional and emerging triggers for cardiovascular inflammation
• Examine the status of therapies that target inflammation in atherosclerosis

FACULTY DISCLOSURES:

Dr. Libby has indicated the following relevant financial relationships with commercial interests: See attached

PLANNING COMMITTEE DISCLOSURE:

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.
Dr. Weiss has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                          Commercial Interest/Organization
Consultant/Contractor                                              Prizm LLC

All the relevant financial relationships for these individuals have been mitigated.

TARGET AUDIENCE:
Primary care physicians.

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.